Studio Makyu Co., Ltd. is a company where Fumihisa Kojima serves as Representative Director.

The company originally focused on web production, DTP design, web marketing, and system development. It has provided broad internet-based business support, including e-commerce sites, customer acquisition for stores, SEO, listing ads, web media operations, and software development. In particular, it has operated multiple compilation and curation-style media sites exceeding 100 million page views per month, and has created and operated buzz media and curation sites.

It later expanded its business areas to include large-scale computation using GPGPU, cryptocurrency mining, blockchain-related systems, AML measures, and bioinformatics support.

The current Biozipcode Group-related businesses also trace one of their starting points to university research support, in silico analysis support, and the construction of GPGPU computing environments that began during the Studio Makyu Co., Ltd. period.

Biozipcode Inc. is a medical and biotech company where Fumihisa Kojima serves as Representative Director.

The business that became the basis for the company began around 2015. Its starting point was Studio Makyu Co., Ltd.’s support for research, including the establishment of a laboratory within the Bio Innovation Center as part of joint research with the Department of Biochemistry and Molecular Biology at Shiga University of Medical Science.

At Studio Makyu Co., Ltd., support was provided not only for conventional in vivo and in vitro research, but also for in silico R&D support. Specifically, the company supported university research from the technical side through the use of bioinformatics tools such as BLAST, the development of proprietary software, and large-scale computational processing using GPGPU.

In January 2022, Biozipcode Inc. was established to carry forward the stream of joint research with Studio Makyu Co., Ltd. Subsequently, in April 2022, a joint research laboratory for the “Regenerative Medicine Development Course” was established within Shiga University of Medical Science, advancing research into novel therapies for intractable diseases including diabetes, as well as research aimed at establishing therapeutic methods using the cell-targeting peptide technology “Biozipcode™”.

Furthermore, in April 2026, the industry-academia joint course “Department of Biocommunication Development” was established at Kyoto University, Graduate School of Medicine and Faculty of Medicine. As joint research with Biozipcode Inc., this course aims to apply cell-targeting technology that selectively recognizes cells and tissues and advance R&D for new therapies for diabetes, cancer, intractable diseases, and related areas.

This represents a constructive transition of the joint research advanced at Shiga University of Medical Science into an industry-academia joint course at Kyoto University. An important role of Biozipcode Inc. is to ensure that research outcomes do not remain only as papers or patents, but are connected to social implementation through collaboration with pharmaceutical companies, medical institutions, and overseas partners.

Today, Biozipcode Inc. focuses primarily on R&D for diabetes, cancer, autoimmune diseases, and other intractable diseases; cell-targeting technology; data analysis; licensing; and in silico R&D support.

Fumihisa Kojima’s role is not to present research outcomes as the researcher himself, but, as Representative Director, to advance fundraising to continue research, maintenance of joint research frameworks, organization of intellectual property, collaboration with business partners, overseas expansion, and social implementation.

Senard Co., Ltd. provides research and database-related services using anti-social-force checks, compliance checks, web crawling, and natural language processing.

As the company’s Chief Technology Officer, Fumihisa Kojima has been involved in building databases related to anti-social forces, web search, compliance check systems, and information gathering using natural language processing.

This experience also informs the design of Web3 projects, investment due diligence, KYC, AML, and risk management.

KIYAN MEDICAL Co., Ltd. is a company aiming to advance R&D and social implementation in medical and drug discovery fields, including diabetes, cell-targeting technology, cancer treatment, and BNCT.

Fumihisa Kojima is involved as a Director of the company. His work mainly centers on areas of collaboration with Biozipcode Inc., including targeting using Biozipcode™ technology, novel therapies for diabetes, and R&D for cancer therapeutics.

KIYAN MEDICAL Co., Ltd. aims to build an integrated framework from R&D to manufacturing and social implementation, backed by its relationship with KIYAN PHARMA Co., Ltd., which has pharmaceutical and manufacturing capabilities.

KIYAN PHARMA Co., Ltd. handles 5-ALA, pharmaceutical APIs and intermediates, health foods, cosmetics, animal health products, fertilizers, feed, and related areas.

As an Executive Officer of the company, Fumihisa Kojima is involved in 5-ALA-related businesses, research concerning diabetes and complications, and the consideration of clinical trial programs.

5-ALA is one of the important themes related to Biozipcode™, diabetes research, overseas medical expansion, and medical tourism concepts.

Auring Ltd. is an overseas company registered in the British Virgin Islands (BVI), positioned as the issuer for Global Development Token, commonly known as GDT.

As Representative Director / Director of Auring Ltd., Fumihisa Kojima is involved in the operation of GDT and related Web3 projects, organizing the issuer-side structure, medical service payments, overseas expansion, and compliance frameworks including KYC and AML.

GDT is designed as a utility token used for access to and payment for actual medical and healthcare services, including diabetes research-related services, medical tourism, biomarker testing, specialist consultations, and 5-ALA-related products.

Within this framework, Auring Ltd. is the corporate entity responsible for token issuance, governance, supply management, wallets, burn design, and ensuring transparency.

GDT is an abbreviation for Global Development Token, a project combining Web3, medical tourism, diabetes research, 5-ALA, biomarker testing, online medical consultations, and related areas.

GDT is positioned as part of the Biozipcode Group concept. It is a concept that combines Web3 mechanisms with social implementation of medical research, overseas medical expansion, access to medical services, 5-ALA-related products, and research support systems.

The industry-academia joint course “Department of Biocommunication Development” at Kyoto University, Graduate School of Medicine and Faculty of Medicine is a research base established as joint research with Biozipcode Inc.

The course aims to apply cell-targeting technology that selectively recognizes cells and tissues and advance R&D for new therapies for intractable diseases.

Fumihisa Kojima is involved not as a Kyoto University researcher, but as Representative Director of Biozipcode Inc., with a role related to social implementation of research outcomes, maintenance of the joint research framework, business collaboration, and financial support.

At Luck Cue Inc., he was involved as Chief Technology Officer in building cryptocurrency mining farms, selling GPU rigs, developing cryptocurrency automated trading software, building web media, and web marketing.

This experience is connected to practical work in GPGPU, mining, and blockchain businesses.

At DMG Blockseer Japan Co., Ltd., he was involved in blockchain analytics, AML, and FinTech compliance.

He gained experience in areas where blockchain and risk management intersect, including cryptocurrency transaction analysis, detection of abnormal transactions, and investigative support for transactions related to criminal funds and money laundering.

At Japan Credit Information Service Co., Ltd., he was involved as Chief Technology Officer in building databases related to anti-social forces, compliance check services, and research system development.

This experience later connected to anti-social-force check and compliance check businesses at Senard Co., Ltd.

At Merchant Bankers Co., Ltd., he was involved as Head of IT Strategy in blockchain, FinTech, NFT, web marketing, and corporate fundraising support.

The company also announced a business alliance with Studio Makyu Co., Ltd. concerning blockchain security, and they collaborated in areas such as cryptocurrency hacking countermeasures, anti-money-laundering measures, and transaction analysis.

This was an important experience connected to his current businesses from the perspectives of collaboration with a listed company, investor relations, fundraising, and external explanation of blockchain businesses.

※Biozipcode Inc. was established with investment from Merchant Bankers Co., Ltd.; however, Fumihisa Kojima later personally purchased all of the shares and made the company independent.

The “Regenerative Medicine Development Course” established within Shiga University of Medical Science was an important joint research base in the formation of Biozipcode’s business.

The course advanced research on the development of novel therapies for intractable diseases including diabetes, establishment of therapeutic methods using the cell-targeting peptide technology “Biozipcode™”, and research related to regenerative medicine, drug discovery, and medical material development.

This joint research laboratory represented the development of research support that had continued since the Studio Makyu Co., Ltd. period into full-scale university joint research under Biozipcode.

Fumihisa Kojima is involved not as a researcher at Shiga University of Medical Science, but through Studio Makyu Co., Ltd. and Biozipcode Inc., in a role responsible for building joint research frameworks, securing research funding, providing technical support, commercialization, maintaining intellectual property, and social implementation.